Chronic
Lyme disease.

The problem no one wants to talk about

If you are reading this, you probably already know what it feels like: you were diagnosed with Lyme disease, you took the antibiotics, and you were told you should be better. But you are not better. You may even have been told that Lyme disease does not persist after treatment, that your symptoms must be caused by something else, or — worst of all — that what you are experiencing is not real.

We want to be very clear: your symptoms are real. The medical debate about chronic Lyme disease is about mechanisms and terminology. It is not about whether you are suffering. That is not in question.

At Klinik St. Georg, we have seen thousands of patients who did not improve with standard Lyme disease treatment. Their stories are remarkably consistent: a period of illness, a course of antibiotics, a temporary improvement (or none at all), and then a slow decline into chronic, multi-system symptoms that no one seems able to explain or treat. We understand this pattern because we have seen it, studied it, and treated it for over 30 years.

Why standard treatment fails

The standard treatment for Lyme disease is a 2–4 week course of oral antibiotics, most commonly doxycycline. For early-stage Lyme disease caught promptly after infection, this treatment is effective in the majority of cases. The problem is that not every case is early-stage, and not every patient is diagnosed promptly.

Delayed diagnosis

Many patients are not diagnosed for months or years after initial infection. Without the classic bull's-eye rash (which is absent in 20–30% of cases), without a remembered tick bite (absent in 50–70% of cases), and with symptoms that develop gradually and mimic other conditions, Lyme disease can evade diagnosis for a long time. By the time these patients receive treatment, the infection has disseminated throughout the body and may have established itself in tissues that are difficult for antibiotics to reach.

Inadequate initial treatment

Some patients receive antibiotics for a shorter duration than recommended, receive an antibiotic that is less effective against Borrelia, or begin treatment too late for a standard course to be sufficient. Guidelines recommend treatment within the first few weeks of infection for optimal outcomes. Patients treated months or years later may require a fundamentally different approach.

Co-infections

Ticks rarely carry only one pathogen. Many Lyme patients are simultaneously infected with Babesia, Bartonella, Ehrlichia, Anaplasma, or other organisms that require different antibiotics or treatment strategies. Standard Lyme treatment does not address these co-infections, and their presence can significantly complicate recovery.

Immune dysfunction

Chronic Borrelia infection can dysregulate the immune system in ways that persist even after bacterial burden is reduced. Inflammatory cascades, autoimmune-like responses, and impaired immune surveillance can perpetuate symptoms long after the acute infection is addressed.

The scientific debate

The existence and nature of chronic Lyme disease is one of the most contentious topics in infectious disease medicine. Understanding the debate is important because it directly affects the care patients receive.

The mainstream position

Organizations like the IDSA (Infectious Diseases Society of America) acknowledge that some patients experience persistent symptoms after standard Lyme treatment. They classify this as "Post-Treatment Lyme Disease Syndrome" (PTLDS) and attribute the ongoing symptoms to a post-infectious inflammatory or autoimmune process — not to persistent active infection. From this perspective, further antibiotic treatment is not warranted because there is, they argue, no active infection to treat.

The clinical position

Organizations like ILADS (International Lyme and Associated Diseases Society) and a growing number of researchers argue that the evidence supports the existence of persistent Borrelia infection that survives standard antibiotic therapy. From this perspective, PTLDS is a misnomer: the symptoms persist because the infection persists, and treatment should be tailored accordingly.

What the research shows

The scientific evidence is more nuanced than either position fully captures:

• Animal studies: Multiple peer-reviewed studies in mice, dogs, and non-human primates have demonstrated that Borrelia can persist in tissues after antibiotic treatment. A landmark 2012 study by Embers et al. found viable Borrelia in multiple tissue sites of treated primates using xenodiagnosis.
• Persister cells: Research by Zhang and colleagues has identified antibiotic-tolerant "persister" forms of Borrelia that can survive standard antibiotic exposure and potentially reactivate when conditions change.
• Biofilms: Borrelia has been shown to form biofilms — protective microbial communities that are inherently resistant to antibiotic penetration — both in vitro and in tissue samples from chronic Lyme patients.
• Tissue sequestration: Borrelia can sequester in tissues with poor antibiotic penetration, including the nervous system, joints, and collagen-rich structures, creating reservoirs that standard oral antibiotics may not reach at therapeutic concentrations.

The case for persistent infection

Understanding why Borrelia can persist despite antibiotic treatment requires understanding the bacteria's remarkable adaptive mechanisms:

Morphological variation

Borrelia burgdorferi can shift between at least three morphological forms: the active spirochete form (which antibiotics target), a dormant "round body" or "cyst" form (which is resistant to most antibiotics), and biofilm aggregates (which provide community-level protection). This morphological flexibility means that antibiotics targeting one form may leave the others untouched.

Immune evasion

Borrelia is one of the most genetically sophisticated pathogens known. It can alter its surface proteins to evade immune detection, suppress local immune responses, and even modulate the host's cytokine profile to create a more favorable environment for persistence. This is not a fragile organism — it is an ancient and highly adapted one.

Tissue tropism

Borrelia has an affinity for specific tissue types, particularly collagen-rich structures like tendons, ligaments, the heart, and the central nervous system. These tissues have relatively poor blood supply and antibiotic penetration, creating natural sanctuaries where the bacteria can persist at low levels.

What patients actually experience

The clinical experience of chronic Lyme disease is remarkably consistent across patients. After years of listening to thousands of patient histories, we recognize the pattern:

• A gradual onset of multi-system symptoms that cannot be explained by a single conventional diagnosis
• Cognitive impairment that is often the most distressing symptom — difficulty thinking, processing information, and maintaining focus
• Profound fatigue that is unrelated to exertion and unresponsive to rest
• Migratory pain that moves between joints, muscles, and nerves without a clear structural explanation
• Sleep disruption that compounds every other symptom
• Psychiatric symptoms — depression, anxiety, irritability — that appeared alongside the physical symptoms, not before them
• A waxing and waning course with good days and bad days, good weeks and bad weeks, that does not follow any predictable pattern
• A medical history filled with dead ends: negative tests, normal imaging, specialist referrals that lead nowhere, and a growing sense of isolation

The most common thing patients tell us when they arrive is not about their symptoms. It is: "Thank you for believing me." After years of being dismissed, validated recognition of their suffering is itself a form of healing.

A different treatment approach

If standard antibiotics are insufficient for chronic Lyme disease, what does effective treatment look like? Based on our three decades of clinical experience, we believe effective treatment must address multiple mechanisms simultaneously:

Target the bacteria directly

Whole-body hyperthermia raises core body temperature to 41.6–41.8°C, a range where Borrelia becomes structurally unstable regardless of its morphological form. This targets both active spirochetes and dormant persister forms in a way that antibiotics alone cannot. The procedure is performed under sedation with continuous monitoring.

Support the immune system

Rather than suppressing immune function (as some autoimmune approaches do), we work to restore and optimize immune competence so the body can participate in clearing the infection. This includes nutritional support, immunomodulatory therapies, and addressing underlying immune deficiencies.

Clear inflammatory debris

H.E.L.P. apheresis can remove circulating immune complexes, inflammatory proteins, and bacterial byproducts from the bloodstream, reducing the inflammatory burden that drives many chronic symptoms.

Address the whole patient

Chronic Lyme disease affects every system. Effective treatment must address sleep, nutrition, mitochondrial function, detoxification, and psychological well-being — not just the infection itself.

For a complete overview of our treatment approaches, visit our treatment options page.

What to do next

If you have been living with chronic Lyme disease, we want you to know three things:

1. Your suffering is real. Regardless of what any test says, regardless of what any doctor has told you, your symptoms are not imaginary and you are not alone.
2. Improvement is possible. We cannot promise cure — no honest physician can. But many of our patients experience significant improvement, and some achieve complete symptom resolution. The outcomes vary, and we will always be transparent about what our experience shows.
3. You deserve to be heard. If you would like a physician who has treated thousands of chronic Lyme patients to review your case, you can share your story here. There is no cost and no obligation. A real doctor reads every submission.

You can also learn more about what Lyme disease is, explore our symptom guide, or take our symptom assessment.